Cardiac troponin I in a representative sample of the Kyrgyz Republic population: distribution, ethnic differences, and association with risk factors

Objective. To assess the distribution of cardiac troponin I (cTnI) in a sample of the Kyrgyz Republic population, to study its associations with risk factors and to identify the possible ethnic differences. Design and methods. This observational cross-sectional study includes a representative sample of the Kyrgyz Republic population aged 20–64 years (n = 1256). The analysis of cTnI levels in the population and associations of cTnI levels with socio-demographic parameters (sex, age, education, etc.), risk factors (smoking, obesity, hypertension, etc.), blood biochemical parameters (triglycerides, lipid profile, glucose) and an anamnesis of cardiovascular diseases and total cardiovascular risk according to the SCORE scale. The statistical significance level was considered equal to 0,05. Results. The median cTnI level in the Kyrgyz sample was 0,90 pg/ml [0,40; 1,80]. The 99^th percentile for the entire sample was 21,4 pg/ml in men and 12,2 pg/ml in women. The median cTnI in the Slavs sample was 1,40 pg/ml [0,60; 2,20]. The 99^th percentile for the entire sample was 21,2 pg/ml in men and 25,2 pg/ml in women. The cTnI level log increases significantly with age in both men and women. At the age of 20-30 years, the cTnI level in men is higher than in women in both ethnic groups. However, with age, the increase rate of cTnI in women is higher than in men in both ethnic groups. In a multivariate analysis, significant associations of cTnI levels with sex, age, hypertension, stroke, blood levels of total cholesterol and triglycerides were obtained. Insufficient accuracy of classification of study participants by SCORE risk was revealed. Conclusions. cTnI is a potential strong biomarker that complements traditional risk scales and is applicable in the framework of cardiovascular diseases primary prevention strategies, which was confirmed in this study on the Kyrgyz Republic population.

1. World Heart Organization fact sheets: cardiovascular disease [cited 2022 Dec 9]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/cardiovasculardiseases-(cvds)

2. Republican Medical Information Center [cited 2022 Dec 9]. Available from: http://cez.med.kg

3. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature. 2008 Feb 21;451(7181):949-52. doi: 10.1038/nature06802

4. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003 Aug 20;290(7):898-904. doi:10.1001/jama.290.7.898

5. Thygesen K, Alpert JS, Jaffe AS, Chaitmanet BR, Bax JJ, Morrow DA et al. ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019;40:237–269. doi:10.1093/eurheartj/ehy462

6. Blankenberg S, Salomaa V, Makarova N, Ojeda F, Wild P, Lackner KJ et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J. 2016 Aug 7;37(30):2428-37. doi:10.1093/eurheartj/ehw172

7. Farmakis D, Mueller C, Apple FS. High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. Eur Heart J. 2020 Nov 1;41(41):4050-4056. doi: 10.1093/eurheartj/ehaa083

8. Farmakis D., Andreadou I., Aessopos A. High-sensitivity troponin assays: Ready for prime-time use as surrogates of subclinical myocardial injury? J. Am. Coll. Cardiol. 2012; 60(2):166. doi:10.1016/j.jacc.2012.02.058

9. Hughes MF, Ojeda F, Saarela O, Jørgensen T, Zeller T, Palosaari T et al. Association of Repeatedly Measured High-Sensitivity-Assayed Troponin I with Cardiovascular Disease Events in a General Population from the MORGAM/BiomarCaRE Study. Clin Chem. 2017 Jan;63(1):334-342. doi: 10.1373/clinchem.2016.261172

10. Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR et al. High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the Atherosclerosis Risk in Communities (ARIC). Study. Circulation. 2019;139(23):2642-53. doi:10.1161/ CIRCULATIONAHA.118.038772

11. Sigurdardottir FD, Lyngbakken MN, Holmen OL, Dalen H, Hveem K, Røsjø H et al. Relative prognostic value of cardiac troponin I and C-reactive protein in the general population (from the HUNT Study). Am J Cardiol. 2018;121:949-55. doi:10.1016/j.amjcard.2018.01.004

12. Willeit P, Welsh P, Evans JDW, Tschiderer L, Boachie C, Jukema JW et al. High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants. JACC. 2017;70:558-68. doi:10.1016/j.jacc.2017.05.062

13. Everett BM, Zeller T, Glynn RJ, Ridker PM, Blankenberg S. High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation. 2015;131(21):1851-60. doi:10.1161/ CIRCULATIONAHA.114.014522

14. Shalnova SA, Drapkina OM, Kontsevaya AV, Yarovaya EB, Kutsenko VA, Metelskaya VA et al. A pilot project to study troponin I in a representative sample of the region from the ESSE-RF study: distribution among population and associations with risk factors. Cardiovascular Therapy and Prevention. 2021;20(4):2940. In Russian. doi:10.15829/1728-8800-2021-2940

15. Shalnova SA, Drapkina OM, Kontsevaya AV, Yarovaya EB, Kutsenko VA, Metelskaya VA, et al. Pilot project to study the association of troponin I with cardiovascular events in the population of Russian region. Cardiovascular Therapy and Prevention. 2021;20(5):2980. In Russian. doi:10.15829/1728-8800-2021-2980

16. Kontsevaya AV, Myrzamatova AO, Polupanov AG, Alikhanova KA, Kashirin AK, Khalmatov AN. Ethnic specifics of the main cardiovascular risk factors prevalence among rural inhabitants of a Russian region and regions of Kyrgyzstan and Kazakhstan. Russian Journal of Cardiology. 2017;(6):113-121. In Russian. doi:10.15829/1560-4071-2017-6-113-121

17. Myrzamatova AO, Kontsevaya AV, Polupanov AG, Altymysheva AT, Kashirin AK, Sirotko ML, et al. Results of a 7-year prospective follow-up in the Interepid study: factors influencing all-cause and cardiovascular mortality in rural residents of Russia and the Kyrgyz Republic. Russian Journal of Cardiology. 2022;27(5):4999. In Russian. doi:10.15829/1560-4071-2022-4999

18. Myrzamatova AO, Kashirin AK, Kontsevaya AV, Sirotko M, Mukaneeva DK, Khudyakov MB. Seven-Year Survival and Associations of Risk Factors with All-Cause and Cardiovascular Mortality among Rural Residents of Samara Region. Ekologiya cheloveka (Human Ecology). 2021, 12, pp. 23-29. In Russian. doi: 10.33396/1728-0869-2021-12-23-29

19. Januzzi JL Jr, Mahler SA, Christenson RH, Rymer J, Newby LK, Body R et al. Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019 Mar 12;73(9):1059-1077. doi: 10.1016/j.jacc.2018.12.046

20. Romiti GF, Cangemi R, Toriello F, Ruscio E, Sciomer S, Moscucci F et al. Sex-Specific Cut-Offs for High-Sensitivity Cardiac Troponin: Is Less More? Cardiovasc Ther. 2019:9546931. doi:10.1155/2019/9546931

21. Welsh P, Preiss D, Hayward C, Shah ASV, McAllister D, Briggs A et al. Cardiac Troponin T and Troponin I in the General Population. Circulation. 2019 Jun 11;139(24):2754-2764. doi: 10.1161/CIRCULATIONAHA.118.038529

22. Leite L, Matos P, Leon-Justel A, Espírito-Santo C, Rodríguez-Padial L, Rodrigues F et al. High sensitivity troponins: A potential biomarkers of cardiovascular risk for primary prevention. Front Cardiovasc Med. 2022 Nov 30;9:1054959. doi: 10.3389/fcvm.2022.1054959

23.